The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models
Tóm tắt
Purpose: Non–small cell lung cancers (NSCLCs) harboring ALK gene rearrangements (ALK+) typically become resistant to the first-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) crizotinib through development of secondary resistance mutations in ALK or disease progression in the brain. Mutations that confer resistance to second-generation ALK TKIs ceritinib and alectinib have also been identified. Here, we report the structure and first comprehensive preclinical evaluation of the next-generation ALK TKI brigatinib.
Experimental Design: A kinase screen was performed to evaluate the selectivity profile of brigatinib. The cellular and in vivo activities of ALK TKIs were compared using engineered and cancer-derived cell lines. The brigatinib–ALK co-structure was determined.
Results: Brigatinib potently inhibits ALK and ROS1, with a high degree of selectivity over more than 250 kinases. Across a panel of ALK+ cell lines, brigatinib inhibited native ALK (IC50, 10 nmol/L) with 12-fold greater potency than crizotinib. Superior efficacy of brigatinib was also observed in mice with ALK+ tumors implanted subcutaneously or intracranially. Brigatinib maintained substantial activity against all 17 secondary ALK mutants tested in cellular assays and exhibited a superior inhibitory profile compared with crizotinib, ceritinib, and alectinib at clinically achievable concentrations. Brigatinib was the only TKI to maintain substantial activity against the most recalcitrant ALK resistance mutation, G1202R. The unique, potent, and pan-ALK mutant activity of brigatinib could be rationalized by structural analyses.
Conclusions: Brigatinib is a highly potent and selective ALK inhibitor. These findings provide the molecular basis for the promising activity being observed in ALK+, crizotinib-resistant patients with NSCLC being treated with brigatinib in clinical trials. Clin Cancer Res; 22(22); 5527–38. ©2016 AACR.
Từ khóa
Tài liệu tham khảo
Grande, 2011, Targeting oncogenic ALK: a promising strategy for cancer treatment, Mol Cancer Ther, 10, 569, 10.1158/1535-7163.MCT-10-0615
Shaw, 2013, Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, N Engl J Med, 368, 2385, 10.1056/NEJMoa1214886
Solomon, 2014, First-line crizotinib versus chemotherapy in ALK-positive lung cancer, N Engl J Med, 371, 2167, 10.1056/NEJMoa1408440
Katayama, 2015, Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine, Clin Cancer Res, 21, 2227, 10.1158/1078-0432.CCR-14-2791
Toyokawa, 2015, Updated evidence on the mechanisms of resistance to ALK inhibitors and strategies to overcome such resistance: clinical and preclinical data, Oncol Res Treat, 38, 291, 10.1159/000430852
Weickhardt, 2012, Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer, J Thorac Oncol, 7, 1807, 10.1097/JTO.0b013e3182745948
Costa, 2015, Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases, J Clin Oncol, 33, 1881, 10.1200/JCO.2014.59.0539
Friboulet, 2014, The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer, Cancer Discov, 4, 662, 10.1158/2159-8290.CD-13-0846
Sakamoto, 2011, CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant, Cancer Cell, 19, 679, 10.1016/j.ccr.2011.04.004
Gadgeel, 2014, Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study, Lancet Oncol, 15, 1119, 10.1016/S1470-2045(14)70362-6
Shaw, 2014, Ceritinib in ALK-rearranged non-small-cell lung cancer, N Engl J Med, 370, 1189, 10.1056/NEJMoa1311107
Ou, 2016, Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study, J Clin Oncol, 34, 661, 10.1200/JCO.2015.63.9443
Ou, 2015, I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib, Lung Cancer, 88, 231, 10.1016/j.lungcan.2015.02.005
Ou, 2014, Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib, J Thorac Oncol, 9, 1821, 10.1097/JTO.0000000000000368
Ou, 2016, ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression, Lung Cancer, 91, 70, 10.1016/j.lungcan.2015.09.006
Iwama, 2014, Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer, Onco Targets Ther, 7, 375
Hatcher, 2015, Discovery of inhibitors that overcome the G1202R anaplastic lymphoma kinase resistance mutation, J Med Chem, 58, 9296, 10.1021/acs.jmedchem.5b01136
Katayama, 2015, Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer, Clin Cancer Res, 21, 166, 10.1158/1078-0432.CCR-14-1385
Shaw, 2016, Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F, N Engl J Med, 374, 54, 10.1056/NEJMoa1508887
Katayama, 2014, Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib, Clin Cancer Res, 20, 5686, 10.1158/1078-0432.CCR-14-1511
Talpaz, 2006, Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias, N Engl J Med, 354, 2531, 10.1056/NEJMoa055229
Kantarjian, 2006, Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL, N Engl J Med, 354, 2542, 10.1056/NEJMoa055104
Cortes, 2013, A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias, N Engl J Med, 369, 1783, 10.1056/NEJMoa1306494
Deininger, 2016, Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients, Blood, 127, 703, 10.1182/blood-2015-08-660977
Smith, 2013, A proposal regarding reporting of in vitro testing results, Clin Cancer Res, 19, 2828, 10.1158/1078-0432.CCR-13-0043
Iwahara, 1997, Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system, Oncogene, 14, 439, 10.1038/sj.onc.1200849
Zhang, 2015, The potent ALK inhibitor AP26113 can overcome mechanisms of resistance to first-and second-generation ALK TKIs in preclinical models, Cancer Res, 75, 781, 10.1158/1538-7445.AM2015-781
Fontana, 2015, Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK, Cancer Med, 4, 953, 10.1002/cam4.413
Ceccon, 2015, Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma, Mol Cancer Res, 13, 775, 10.1158/1541-7786.MCR-14-0157
Huang, 2016, Discovery of brigatinib (AP26113), a phosphine oxide-containing, potent, orally active inhibitor of anaplastic lymphoma kinase, J Med Chem, 59, 4948, 10.1021/acs.jmedchem.6b00306
Gettinger, Brigatinib (AP26113) efficacy and safety in ALK+ NSCLC: phase 1/2 trial results, J Thorac Oncol, 10, S238
Gehrke, 2011, Clinical pharmacology review. Xalkori, crizotinib
Brigatinib (data on file)
Ou, 2013, Safety and efficacy analysis of RO5424802/CH5424802 in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients who have failed crizotinib in a dose-finding phase I study (AF-002JG, NCT01588028), Eur J Cancer, 49, S19
Brower, 2014, Clinical pharmacology review. Zykadia, ceritinib
Zahalka, 2015, Clinical pharmacology review. Alecensa, alectinib